FCPM III SERVICES B.V.
NAARDEN, P7 · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$1.06B2026 Q3
Positions15
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.96.4%
What Changed This Quarter?
Top Holdings
BRVE
Braveheart Bio
41.6%
NAMS
NewAmsterdam Pharma Co
19.5%
KRSA
Korsana Biosciences
6.6%
VOR
Vor Biopharma
6.1%
DYN
Dyne Therapeutics
5.4%
Damora Therap…
Damora Therapeutics
4.9%
MPLT
MapLight Therapeutics
4.3%
AURA
Aura Biosciences
3.1%
New / Increased
4 new · 3 increased
BRVENEW
Braveheart Bio
41.6%
KRSANEW
Korsana Biosciences
6.6%
TARSNEW
Tarsus Pharmaceuticals
0.5%
LSTANEW
Lisata Therapeutics
0.0%
MPLT
Maplight Therapeutics
4.3%
+37.3%
AURA
Aura Biosciences
3.1%
+29.5%
CBIO
Crescent Biopharma
2.8%
+20.6%
Reduced / Exited
3 reduced · 0 sold out
REPL
Replimune
2.1%
-38.7%
VOR
Vor Biopharma
6.1%
-17.3%
DYN
Dyne Therapeutics
5.4%
-6.8%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.